- Home
- WNW vs APM Comparison
WNW vs APM Comparison
Compare WNW & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- APM
- Stock Information
- Founded
- WNW 2015
- APM 2010
- Country
- WNW China
- APM United Kingdom
- Employees
- WNW N/A
- APM N/A
- Industry
- WNW Catalog/Specialty Distribution
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- APM Health Care
- Exchange
- WNW Nasdaq
- APM Nasdaq
- Market Cap
- WNW 6.9M
- APM 6.1M
- IPO Year
- WNW 2020
- APM 2018
- Fundamental
- Price
- WNW $1.71
- APM $1.07
- Analyst Decision
- WNW
- APM
- Analyst Count
- WNW 0
- APM 0
- Target Price
- WNW N/A
- APM N/A
- AVG Volume (30 Days)
- WNW 26.2K
- APM 81.2K
- Earning Date
- WNW 07-07-2025
- APM 06-17-2025
- Dividend Yield
- WNW N/A
- APM N/A
- EPS Growth
- WNW N/A
- APM N/A
- EPS
- WNW 9.06
- APM N/A
- Revenue
- WNW $158,485.00
- APM N/A
- Revenue This Year
- WNW N/A
- APM N/A
- Revenue Next Year
- WNW N/A
- APM N/A
- P/E Ratio
- WNW $0.19
- APM N/A
- Revenue Growth
- WNW N/A
- APM N/A
- 52 Week Low
- WNW $0.95
- APM $0.46
- 52 Week High
- WNW $70.00
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- WNW 44.39
- APM 58.89
- Support Level
- WNW $1.62
- APM $0.83
- Resistance Level
- WNW $1.80
- APM $1.35
- Average True Range (ATR)
- WNW 0.12
- APM 0.12
- MACD
- WNW 0.02
- APM 0.02
- Stochastic Oscillator
- WNW 32.62
- APM 46.97
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.